Molbio Diagnostics is set to debut on the stock market on August 17, with its shares listed on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE), according to livemint.com. The IPO allotment was finalized on August 13 following a strong subscription period that ended on August 12.
The initial public offering (IPO) opened for subscription on August 10 and closed on August 12, attracting bids for 57,32,14,536 shares against an issue size of 81,58,500 shares. This resulted in an overall subscription rate of 70.26 times, reflecting robust investor interest during the three-day bidding window, livemint.com reported.
The high subscription rate underscores strong market demand for Molbio Diagnostics, a company operating in the diagnostics sector. This IPO is significant given the competitive landscape of healthcare-related public offerings in India. The listing on both NSE and BSE provides investors with broad access to trade the stock, aligning with recent trends of increased investor participation in healthcare and diagnostics companies.
Molbio Diagnostics’ shares will officially start trading on August 17, marking a key milestone for the company and investors who participated in the IPO. The allotment finalized on August 13 sets the stage for market activity and price discovery on the debut day, as detailed by livemint.com.